To compare safety and efficacy of cyclosporine 0.05% and cyclosporine 0.09% eyedrops for dry eye (keratoconjunctivitis).

Phase 4

• Conditions: Dry Eye Syndrome

• Registration Number: JPRN-UMIN000035991
• Lead Sponsor: aser Eye Clinic Noida

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-02-24
• Study Completion: 2019-05-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Not provided

Exclusion Criteria

Patients with current ocular infection, history of laser in situ keratomileusis, allergic conjunctivitis, herpetic eye disease, diabetes, and liver diseases were excluded. Other exclusion criteria were pregnant or lactating mothers, HIV, and hepatitis B and C. Patients who were allergic to fluorescein were excluded. Systemic (tetracyclines and corticosteroids) or topical medications (other than artificial tear supplements) that could affect tear production or meibomian gland functions were discontinued before intervention. However, patients were instructed not to use artificial tear preparations, 2 hours before testing. Computer work was not allowed during the course of the study as concurrent use of visual display terminals may independently influence ocular surface changes.

Study & Design

• Study Type: Interventional
• Study Design: Not specified